Financial News

Johnson & Johnson 3Q Results

Growth in the quarter driven by DARZALEX, CARVYKTI, ERLEADA in Oncology, TREMFYA and SIMPONI in Immunology, and SPRAVATO in Neuroscience.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson

Johnson & Johnson 3Q Revenues: $24.0 billion (+7%) 3Q Earnings: $5.2 billion (+91%) YTD Revenues: $69.6 billion (+5%) YTD Earnings: $21.7 billion (+104%) Comments: Growth in the quarter was primarily driven by DARZALEX, CARVYKTI, ERLEADA and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and SIMPONI/SIMPONI ARIA in Immunology, and SPRAVATO in Neuroscience.  DARZALEX sales were up 22% to $3.7 billion. CARVYKTI sales were up 84% to $524 million. ERLEADA sales were up 18% to $93...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics